All News

2021

June

Media Release / Jun 23, 2021

Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Read More
Media Release / Jun 23, 2021

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

Read More
Media Release / Jun 22, 2021

Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosis

Read More
Trees
Story / Jun 21, 2021

The search for new options for patients with lung cancer

We’re working to bring the hope of advanced medicine to more patients.

Read More
Artist’s depiction of the inflammasome.
Story / Jun 21, 2021

Discover how inflammation could fan the flames of cancer

Targeting inflammation to fight cancer is a new approach with a long history.

Read More
Media Release / Jun 18, 2021

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

Read More
Featured News / Jun 16, 2021

Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Read More
In The News / Jun 16, 2021

Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen

Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.

Read More
Media Release / Jun 11, 2021

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Read More
Featured News / Jun 10, 2021

Novartis Entresto® indicated for treatment of hypertension in China

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More